| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cardiology, Karolinska Hospital, Stockholm, S-171 76 Sweden
The interaction between the cardioprotective effect of endothelin (ET) receptor blockade and nitric oxide (NO) during ischemia-reperfusion injury was investigated. Anesthetized pigs were subjected to 45 (protocol 1) or 30 min (protocol 2) coronary artery ligation and 4 h reperfusion. In protocol 1, five groups were given vehicle, the ETA receptor antagonist LU-135252 (LU), the NO synthase (NOS) inhibitor NG-nitro-L-arginine (L-NNA), L-NNA in combination with LU, or L-NNA in combination with the NO precursor L-arginine (L-Arg) and LU intravenously before ischemia. In protocol 2, two groups were given vehicle or L-NNA. In protocol 1, the infarct size (IS) was 79 ± 5% of the area at risk in the vehicle group and 93 ± 2% in the L-NNA group. LU reduced the IS to 43 ± 7% (P < 0.001). The cardioprotective effect of LU was abolished in the presence of L-NNA (IS 76 ± 6%), whereas addition of L-Arg restored its cardioprotective effect (IS 56 ± 2%; P < 0.05 vs. vehicle and L-NNA + LU groups). In protocol 2, the IS was 49 ± 6% in the vehicle group and 32 ± 4% in the L-NNA group (P = not significant). Myocardial ET-like immunoreactivity (ET-LI) increased in the vehicle group of protocol 1. ET-LI in the ischemic-reperfused myocardium was lower in the groups given LU (P < 0.01) and L-NNA + L-Arg + LU (P < 0.05) but not in the group given L-NNA + LU compared with the vehicle group. These results suggest that the cardioprotective effect of the ETA receptor antagonist is mediated via a mechanism related to NO.
reperfusion injury
This article has been cited by other articles:
|
|
 |
|
  K. Trescher, M. Bauer, W. Dietl, S. Hallstrom, N. Wick, M. Wolfsberger, R. Ullrich, G. Jurgens, E. Wolner, and B. K. Podesser Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J Epstein Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist Ann. Pharmacother., July 1, 2008; 42(7): 1060 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Baltogiannis, D. G. Tsalikakis, A. C. Mitsi, K. E. Hatzistergos, D. Elaiopoulos, D. I. Fotiadis, Z. S. Kyriakides, and T. M. Kolettis Endothelin receptor-A blockade decreases ventricular arrhythmias after myocardial infarction in rats Cardiovasc Res, September 1, 2005; 67(4): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, N. Ahmad, M. Kudo, and M. Ashraf Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1125 - H1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Gonon, D. Erbas, A. Broijersen, G. Valen, and J. Pernow Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1767 - H1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castella, G. D. Buckberg, Z. Tan, and L. J. Ignarro Myocyte and endothelial effects of preconditioning the jeopardized heart by inhibiting Na+/H+ exchange J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1113 - 1121. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Gao, E. Gao, T.-L. Yue, E. H. Ohlstein, B. L. Lopez, T. A. Christopher, and X.-L. Ma Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial Ischemia-Reperfusion: The Roles of PI3-Kinase, Akt, and Endothelial Nitric Oxide Synthase Phosphorylation Circulation, March 26, 2002; 105(12): 1497 - 1502. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
